Can’t see the audio player? Click here to listen on SoundCloud. An estimated 9 million Americans eligible for free or reduced…
Home » Medications »
FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.…
FDA Approves Breyanzi
FDA Approves Breyanzi (lisocabtagene maraleucel) CAR-T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma PRINCETON, N.J.–(BUSINESS WIRE)…
KHN’s ‘What the Health?’: Covid and Kids
Can’t see the audio player? Click here to listen on SoundCloud. Nearly a year into the pandemic, many public schools are…
FDA Approves Posimir
FDA Approves Posimir (bupivacaine) for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression CUPERTINO, Calif., Feb.…
Flumazenil APOTEX
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. FLUMAZENIL APOTEX SOLUTION FOR INJECTION Contains the…
APO-Pregabalin
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APO-PREGABALIN Contains the active ingredient pregabalin Consumer…
Osteovan
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. OSTEOVAN® Zoledronic acid Consumer Medicine Information What…
Somatuline LA
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. SOMATULINE®LA 30MG Lanreotide Consumer Medicine Information What…
Inderal
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. INDERAL® propranolol hydrochloride Consumer Medicine Information What…